leptin vs glp 1 Figure 2 from Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes Ghrelin and Leptin

GLP-1 receptor agonistswhich are currently FDA-approved for people who are obese (a BMI of 30 or greater), have type 2 diabetes, or are overweight (a BMI of at least 27) and have cardiovascular disease or other risk factorsare emerging as a promising non-hormonal option for cardiometabolic protection during menopause

Oral toxicity of silver ions, silver nanoparticles and colloidal silvera review

Examples are MTHFR variants, which impact folate metabolism and homocysteine, FTO and MC4R, which are associated with weight regulation, CYP19A1, which is involved in aromatase and estrogen balance, ESR1 and ESR2, which are estrogen receptors, and variants in FSHR and LHCGR that alter ovarian response

compounding pharmacies, dosed using your labs and health history, and monitored over time